Novartis AG Company Profile (NYSE:NVS)

About Novartis AG (NYSE:NVS)

Novartis AG logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NYSE:NVS
  • CUSIP: N/A
  • Web:
  • Market Cap: $190.74 billion
  • Outstanding Shares: 2,365,595,000
Average Prices:
  • 50 Day Moving Avg: $77.31
  • 200 Day Moving Avg: $74.14
  • 52 Week Range: $66.93 - $83.58
  • Trailing P/E Ratio: 30.31
  • Foreward P/E Ratio: 15.60
  • P/E Growth: 3.14
Sales & Book Value:
  • Annual Revenue: $49.36 billion
  • Price / Sales: 3.86
  • Book Value: $28.57 per share
  • Price / Book: 2.82
  • Annual Dividend: $2.30
  • Dividend Yield: 3.3%
  • EBIDTA: $14.34 billion
  • Net Margins: 13.80%
  • Return on Equity: 15.37%
  • Return on Assets: 8.57%
  • Debt-to-Equity Ratio: 0.24%
  • Current Ratio: 1.12%
  • Quick Ratio: 0.84%
  • Average Volume: 2.57 million shs.
  • Beta: 0.73
  • Short Ratio: 1.36

Frequently Asked Questions for Novartis AG (NYSE:NVS)

What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG announced an annual dividend on Friday, January 27th. Investors of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date of this dividend is Wednesday, March 1st. View Novartis AG's Dividend History.

How will Novartis AG's stock buyback program work?

Novartis AG announced that its board has initiated a share buyback plan on Saturday, April 8th 2017, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's management believes its shares are undervalued.

How were Novartis AG's earnings last quarter?

Novartis AG (NYSE:NVS) posted its quarterly earnings results on Tuesday, April, 25th. The company reported $1.13 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.10 by $0.03. The business earned $11.54 billion during the quarter, compared to the consensus estimate of $11.59 billion. Novartis AG had a return on equity of 15.37% and a net margin of 13.80%. Novartis AG's revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the business earned $1.17 earnings per share. View Novartis AG's Earnings History.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

14 brokerages have issued 12 month price targets for Novartis AG's shares. Their forecasts range from $74.37 to $92.00. On average, they anticipate Novartis AG's stock price to reach $82.09 in the next twelve months. View Analyst Ratings for Novartis AG.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph Jimenez, Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
  • Steven Baert, Head of Human Resources, Member of the Executive Committee
  • Vasant Narasimhan M.D., Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee

Who owns Novartis AG stock?

Novartis AG's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (0.92%), Wells Fargo & Company MN (0.38%), Parnassus Investments CA (0.35%), Bank of America Corp DE (0.31%), Loomis Sayles & Co. L P (0.26%) and Fisher Asset Management LLC (0.26%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, JPMorgan Chase & Co., Ameriprise Financial Inc., Lazard Asset Management LLC, United States Steel & Carnegie Pension Fund, Advisors Capital Management LLC, State Street Corp and PNC Financial Services Group Inc.. View Insider Buying and Selling for Novartis AG.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was purchased by a variety of institutional investors in the last quarter, including Parnassus Investments CA, BlackRock Inc., Janus Capital Management LLC, Wells Fargo & Company MN, Karp Capital Management Corp, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and Point72 Asset Management L.P.. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis AG's stock price today?

One share of Novartis AG stock can currently be purchased for approximately $80.63.

MarketBeat Community Rating for Novartis AG (NYSE NVS)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  428
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novartis AG (NYSE:NVS) (?)
Ratings Breakdown: 2 Sell Ratings, 7 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $82.09 (1.81% upside)

Analysts' Ratings History for Novartis AG (NYSE:NVS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/18/2017JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
4/5/2017Cowen and CompanyDowngradeOutperform -> Market Perform$87.00 -> $77.00LowView Rating Details
3/22/2017Goldman Sachs Group IncReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/11/2017Credit Suisse Group AGDowngradeOutperform -> NeutralN/AView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
7/12/2016Bank of America CorpReiterated RatingHoldN/AView Rating Details
5/24/2016Citigroup IncReiterated RatingNeutralN/AView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
4/12/2016Morgan StanleyDowngradeEqual Weight -> UnderweightN/AView Rating Details
11/23/2015VontobelDowngradeHoldN/AView Rating Details
10/28/2015Sanford C. BernsteinLower Price TargetOutperform$102.00N/AView Rating Details
10/28/2015Main First Bank AGDowngradeUnderperformN/AView Rating Details
7/7/2015Oddo SecuritiesInitiated CoverageBuyN/AView Rating Details
6/25/2015HSBC Holdings plcInitiated CoverageBuyN/AView Rating Details
6/22/2015Bryan, Garnier & CoUpgradeNeutral -> BuyN/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Novartis AG (NYSE:NVS)
Earnings by Quarter for Novartis AG (NYSE:NVS)
Earnings History by Quarter for Novartis AG (NYSE:NVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.88
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20171$1.22$1.22$1.22
Q3 20171$1.25$1.25$1.25
Q4 20171$1.29$1.29$1.29
(Data provided by Zacks Investment Research)


Current Dividend Information for Novartis AG (NYSE:NVS)
Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.85%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:82.14% (Trailing 12 Months of Earnings)
48.94% (Based on This Year's Estimates)
44.49% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Dividend History by Quarter for Novartis AG (NYSE:NVS)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novartis AG (NYSE:NVS)
Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 9.82%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novartis AG (NYSE:NVS)
Latest Headlines for Novartis AG (NYSE:NVS)
DateHeadline logoCambridge largely spared as Novartis cuts hundreds of jobs - May 24 at 7:07 PM logoThe Current State Of The Breast Cancer Treatment Space - May 23 at 6:26 PM logoNovartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion - May 23 at 10:06 AM logoNovartis set for 39 data presentations at ASCO - Seeking Alpha - May 20 at 11:33 PM logoNovartis to cut around 500 jobs in Switzerland, add 350 - May 19 at 7:29 PM logoNovartis: Follow The (Belgian) Yellow Brick Road - Seeking Alpha - May 19 at 11:43 AM logoNovartis set for 15 data presentations at ASCO - Seeking Alpha - May 19 at 11:43 AM logoCHMP backs Novartis's Zykadia for first-line use in lung cancer - May 19 at 11:43 AM logoAmgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab - May 19 at 11:43 AM logoToday's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis - May 16 at 10:09 AM logoNovartis AG (NVS) Given Average Rating of "Hold" by Brokerages - May 15 at 2:46 PM logoGlaxoSmithKline Could Buy Out Partner Novartis - May 15 at 10:06 AM logoWhat Is Sparking Novartis Shares This Spring? - Seeking Alpha - May 12 at 12:27 AM logo[$$] Novartis Has the Right Prescription for Profits - May 6 at 8:42 AM logoBlog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan - May 5 at 9:02 AM logoSomewhat Favorable Media Coverage Likely to Impact Novartis AG (NVS) Stock Price - May 4 at 10:00 PM logoNovartis, Roche back French gene therapy start-up Vivet - May 4 at 7:05 PM logoOphthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss - May 4 at 7:05 PM logoGreatmark Investment Partners, Inc. Buys Novartis AG, Chesapeake Energy Corp, Coherent Inc, ... - May 3 at 8:07 PM logoStem cell biotech Magenta bags $50M, strikes licensing deal with Novartis - May 2 at 11:19 AM logoHow GlaxoSmithKline’s Vaccines Business Performed in 1Q17 - May 2 at 11:19 AM logoCambridge's bluebird bio licenses delivery tech to Novartis, GSK - May 2 at 11:19 AM logoETFs with exposure to Novartis AG : May 1, 2017 - May 1 at 5:52 PM logoNovartis AG (NVS) Upgraded to "Hold" by Zacks Investment Research - May 1 at 5:22 PM logoNovartis AG (NVS) Receives Daily Coverage Optimism Rating of 0.28 - May 1 at 3:32 PM logoNovartis’s Valuation after 1Q17 Earnings - May 1 at 12:09 PM logoHow GlaxoSmithKline’s Business Segments Performed in 1Q17 - May 1 at 12:09 PM logoNovartis AG (NVS) to Post FY2017 Earnings of $4.71 Per Share, Jefferies Group Forecasts - May 1 at 9:46 AM logoHow Far Into the Drug Pipeline Should the FTC Reach? - April 30 at 8:10 PM logoResearch Analysts Set Expectations for Novartis AG's FY2020 Earnings (NVS) - April 29 at 12:46 AM logo1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business - April 28 at 7:56 PM logoNovartis’s 1Q17 Earnings: Recent Developments - April 28 at 7:56 PM logoNovartis AG :NVS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 - April 28 at 7:56 PM logoU.S. FDA approves Novartis' leukemia treatment - April 28 at 7:56 PM logoNovartis AG (NVS) Receiving Somewhat Negative News Coverage, Analysis Finds - April 28 at 2:51 PM logo1Q17 Earnings for Novartis’s Sandoz, Its Generics Business - April 28 at 8:45 AM logoJerome Dodson Comments on Novartis - April 27 at 7:25 PM logoWhy Novartis’s 1Q17 Revenues Missed Analysts’ Estimates - April 27 at 7:25 PM logoNovartis’s 1Q17 Earnings: Segment Performances - April 27 at 7:25 PM logoNovartis’s 1Q17 Earnings: Innovative Medicines Segment - April 27 at 7:25 PM logoEarnings Reaction History: Novartis AG, 42.9% Follow-Through Indicator, 1.2% Sensitive - Nasdaq - April 26 at 11:21 PM logoNovartis AG (NVS) Q1 2017 Results - Earnings Call Transcript - April 26 at 6:19 PM logoGlaxoSmithKline’s 1Q17 Estimates: Vaccines Business - April 26 at 6:19 PM logoGlaxo (GSK) Beats Earnings and Revenues in Q1 - April 26 at 6:19 PM logoVetr Inc. Downgrades Novartis AG (NVS) to Hold - April 26 at 12:14 AM logoAutism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders - April 25 at 6:09 PM logoNovartis Q1 Core Profit Tops Estimates; Backs; Backs FY17 View; Shares Up - April 25 at 6:09 PM logoNovartis Q1 Profit Down On Weak Sales; Backs FY17 View - Quick Facts - April 25 at 6:09 PM logoSwiss drugs giant Novartis posts 15 percent drop in profit - April 25 at 6:09 PM logoNovartis to speed up bid for MS drug approval, changes target - April 25 at 6:09 PM



Novartis AG (NVS) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff